Bamberger M: Difference between revisions
From Bioblast
Beno Marija (talk | contribs) (Created page with "{{person}}") |
Beno Marija (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
{{ | {{Person | ||
|lastname=Bamberger | |||
|firstname=Mark | |||
|title=PhD | |||
Chief Scientific researcher | |||
|institution=Stealth BioTherapeutics | |||
|address=275 Grove Street | |||
|area code=02466 | |||
|city=Newton | |||
|state=Massachusetts (MA) | |||
|country=United States | |||
|mailaddress=mark.bamberger@stealthbt.com | |||
|weblink=https://www.stealthbt.com/our-company/ | |||
}} | |||
{{Labelingperson}} |
Revision as of 08:26, 7 August 2018
Name | Bamberger Mark, PhD
Chief Scientific researcher |
---|---|
Institution | Stealth BioTherapeutics |
Address | 275 Grove Street, 02466 |
City | Newton |
State/Province | Massachusetts (MA) |
Country | United States |
mark.bamberger@stealthbt.com | |
Weblink | https://www.stealthbt.com/our-company/ |
O2k-Network Lab |
Labels:
Publications
Add references to your publications
Abstracts
Published | Reference | |
---|---|---|
Bamberger 2018 MiP2018 | 2018 | Discovery and development of elamipretide: targeting mitochondrial dysfunction in rare and common disease. |